The NEVER STOP campaign comes to London, U.K., as FUJIFILM representatives speak at FT Global Pharmaceutical and Biotechnology Conference
On Monday 5 and Tuesday 6 November, FUJIFILM sponsored the Financial Times’ 36th annual Global Pharmaceutical and Biotechnology Conference hosted at the Royal Lancaster Hotel, London – the leading event for getting a glimpse of the future of healthcare.
The event brought together more than 300 of the healthcare industry’s top executives and visionaries to explore the latest trends set to reshape the industry far into the future - from new R&D models and digital diagnostics to patient centricity and new models for cross-industry partnerships and collaborations.
Utilising of the branding of Fujifilm’s NEVER STOP campaign, thought leaders from two of Fujifilm’s leading healthcare businesses – FUJIFILM Medical Systems Europe and FUJIFILM Diosynth Biotechnologies – shared their expert insight and Fujifilm’s expertise in biotechnology and diagnostics, underscoring Fujifilm’s commitment to help medical professionals and pharmaceutical companies around the world better prevent, diagnose and treat conditions.
The NEVER STOP campaign's core message aims to highlight Fujifilm's firm and unwavering commitment to achieving continued corporate growth and never stop building on our innovations and expertise. The campaign represents Fujifilm's success in transitioning itself from a company focused on photographic film to a company providing new value across a wide range of different fields, contributing to the resolution of various societal issues – including healthcare.
The ‘Envisioning the Future of Diagnostics’ panel discussion, chaired by Greg Reh, Global Life Sciences and Healthcare Industry Leader, Deloitte, featured FUJIFILM Medical Systems Europe's Kevin Shah, Head of Enterprise New Business. Kevin Shah appeared alongside industry leaders from Google Cloud, Color Genomics, Alexion Pharmaceuticals and Owlstone Medical.
This discussion covered all the latest trends in cutting-edge diagnostics, including the impact of AI - artificial intelligence - to the introduction of tailored therapeutics.
The 'Partnerships and Collaborations' panel discussion, chaired by Vanessa Houlder, Lex Writer, Financial Times, featured FUJIFILM Diosynth Biotechnologies' Dr. Mark Douglas, Vice President, Strategic Business Development. Dr. Mark Douglas appeared alongside industry leaders from Mundipharma Research and the U.K.'s National Institute for Health Research.
This discussion aimed to provide visibility regarding what’s working and not working in the multiple types of partnering and collaborations being undertaken and explored by life sciences companies-from joint ventures, to licensing to consortia and tie-ups increasingly with non-traditional industry players.
Fujifilm Corporation is a wholly-owned subsidiary of Fujifilm Holdings Corporation.